查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1585794

脑肿瘤诊断市场：按测试类型、脑肿瘤类型、最终用户划分 - 全球预测 2025-2030

Brain Cancer Diagnostics Market by Test Type (Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, PET Scan), Brain Cancer Type (Acoustic Neuroma, Astrocytomas, Chordomas), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年脑瘤诊断市场价值为40.2亿美元，预计到2024年将达到45.2亿美元，复合年增长率为12.44%，到2030年将达到91.4亿美元。

脑肿瘤诊断市场的范围包括广泛的技术和方法，包括诊断影像技术（MRI、 电脑断层扫描）、切片检查、组织学评估以及液态切片和次世代定序。这些诊断对于早期检测、确定最有效的治疗策略以及监测疾病进展和復发至关重要。应用范围从医院实验室到癌症中心，最终用户包括肿瘤学家、神经外科医生、病理学家以及更多依赖这些工具进行精准医疗的人。脑肿瘤发生率的上升和诊断技术的进步正在推动市场成长。此外，对个人化医疗和标靶治疗的认识不断增强，为开发新型诊断方法的公司带来了巨大的市场机会。

主要市场统计
基准年[2023] 40.2亿美元
预测年份 [2024] 45.2亿美元
预测年份 [2030] 91.4亿美元
复合年增长率（%） 12.44%

关键的成长要素包括诊断成像和基因组分析的人工智慧和机器学习等技术进步，从而提高诊断准确性和效率。然而，市场面临一些挑战，例如先进诊断工具的高成本、诊断准确性的差异以及新兴地区的准入有限。监管障碍和对技术人员解释复杂诊断资料的需求进一步阻碍了成长。扩大远端医疗和远距离诊断能力存在潜在的商机，这可以使全球高品质诊断的获取更加民主。此外，生技公司和学术机构之间的合作可以加速创新诊断工具的研发。

非侵入性诊断方法的创新，例如基于血液的测试和具有更高灵敏度和特异性的改进成像技术，是有前景的研究和市场成长领域。促进整个医疗保健生态系统的协作，以简化资料共用并将诊断工具整合到综合护理路径中是向前迈出的关键一步。儘管存在固有的挑战，但在技术创新和对改善临床结果的不断追求的推动下，脑肿瘤诊断市场正在朝着更全面、以患者为中心的方法发展。公司应该利用人工智慧和个人化医疗的趋势来保持竞争力并推动这个充满活力的领域的未来成长。

市场动态：快速发展的脑肿瘤诊断市场的关键市场洞察

供需的动态交互作用正在改变脑肿瘤诊断市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 脑肿瘤发生率增加
    • 私人诊断中心数量的增加和公私合营的加强
  • 市场限制因素
    • 诊断费用高，诊断意识低
  • 市场机会
    • 诊断设备的技术进步
    • 开发各种癌症突变的诊断方法
  • 市场挑战
    • 高辐射暴露风险增加和严格的监管指南

波特五力：驾驭脑瘤诊断市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对脑肿瘤诊断市场的影响

外部宏观环境因素在塑造脑肿瘤诊断市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解脑肿瘤诊断药物市场竞争状况

对脑肿瘤诊断市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵脑瘤诊断市场供应商绩效评估

FPNV定位矩阵是评估脑肿瘤诊断市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘脑肿瘤诊断市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对脑肿瘤诊断市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 脑肿瘤发生率增加
      • 增加私人诊断中心的数量并扩大公私合营
    • 抑制因素
      • 诊断费用高、诊断认知度低
    • 机会
      • 诊断设备的技术进步
      • 开发各种癌症突变的诊断方法
    • 任务
      • 高辐射暴露风险增加和严格的监管指南
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章按测试类型分類的脑肿瘤诊断市场

  • 磁振造影
  • 磁共振波谱
  • 正子断层扫描
  • 脊椎穿刺

第七章以脑肿瘤类型分類的脑肿瘤诊断药物市场

  • 听神经瘤
  • 星状细胞瘤
  • 脊索瘤
  • 室管膜瘤

第八章脑肿瘤诊断市场：依最终用户分类

  • 诊断中心
  • 医院/诊所

第九章 北美、南美洲脑瘤诊断药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区脑肿瘤诊断市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的脑肿瘤诊断市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Associated Regional and University Pathologists, Inc.
  • Becton, Dickinson and Company
  • Bristol Myers Squibb Co.
  • F. Hoffmann-La Roche AG by Roche Holding AG
  • Fujifilm Holdings Corporation
  • GE Healthcare
  • Grail, LLC
  • Henry Ford Health
  • Hitachi, Ltd.
  • Hologic, Inc.
  • Illumina, Inc.
  • Invitae Corporation
  • Koninklijke Philips NV
  • Laboratory Corporation of America Holdings
  • NantOmics
  • NeoGenomics Laboratories, Inc.
  • Novocure GmbH
  • Oncologica Limited
  • Quibim, SL
  • Siemens Healthineers AG
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-A26E0E57412A

The Brain Cancer Diagnostics Market was valued at USD 4.02 billion in 2023, expected to reach USD 4.52 billion in 2024, and is projected to grow at a CAGR of 12.44%, to USD 9.14 billion by 2030.

The scope of the brain cancer diagnostics market encompasses a broad range of technologies and methods, including imaging techniques (MRI, CT scans), biopsy and histological assessments, and emerging molecular diagnostic tools such as liquid biopsies and next-generation sequencing. These diagnostics are crucial for early detection, determining the most effective therapeutic strategies, and monitoring disease progression or recurrence. Applications span from hospital-based laboratories to specialized oncology centers, with end-users including oncologists, neurosurgeons, and pathologists who rely on these tools for precision medicine. The rising incidence of brain tumors, coupled with advancements in diagnostics technologies, drives market growth. Additionally, increased awareness of personalized medicine and targeted therapies highlights significant market opportunities for companies developing novel diagnostic approaches.

KEY MARKET STATISTICS
Base Year [2023] USD 4.02 billion
Estimated Year [2024] USD 4.52 billion
Forecast Year [2030] USD 9.14 billion
CAGR (%) 12.44%

Key growth factors include technological advancements, such as AI and machine learning in imaging and genomic profiling, leading to enhanced diagnostic accuracy and efficiency. However, the market faces challenges including high costs associated with advanced diagnostic tools, variability in diagnostic accuracy, and limited accessibility in developing regions. Regulatory hurdles and the need for skilled personnel to interpret complex diagnostic data further inhibit growth. Potential opportunities exist in the expansion of telehealth and remote diagnostic capabilities, which could democratize access to high-quality diagnostics worldwide. Moreover, partnerships between biotech firms and academic institutions could accelerate the research and development of innovative diagnostic tools.

Innovation in non-invasive diagnostic methods, such as blood-based tests or improved imaging techniques with higher sensitivity and specificity, presents a promising area for research and market growth. Fostering collaborations across the healthcare ecosystem to streamline data sharing and integrate diagnostic tools into comprehensive care pathways are crucial steps forward. Despite inherent challenges, the brain cancer diagnostics market is evolving towards a more integrated, patient-centered approach, driven by technological innovation and the continuous quest for improved clinical outcomes. Businesses should capitalize on advancements in AI and personalized medicine trends to stay competitive and drive future growth in this dynamic sector.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Brain Cancer Diagnostics Market

The Brain Cancer Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidence of brain cancer
    • Growth in the number of private diagnostic centers and rising public-private partnerships
  • Market Restraints
    • Heavy costs associated with diagnosis and low awareness about the diagnosis
  • Market Opportunities
    • Technological advancement in diagnostics devices
    • Development of diagnostic approaches for various cancer mutations
  • Market Challenges
    • Rising risk of high radiation exposure and stringent regulatory guidelines

Porter's Five Forces: A Strategic Tool for Navigating the Brain Cancer Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Brain Cancer Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Brain Cancer Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Brain Cancer Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Brain Cancer Diagnostics Market

A detailed market share analysis in the Brain Cancer Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Brain Cancer Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Brain Cancer Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Brain Cancer Diagnostics Market

A strategic analysis of the Brain Cancer Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Brain Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Associated Regional and University Pathologists, Inc., Becton, Dickinson and Company, Bristol Myers Squibb Co., F. Hoffmann-La Roche AG by Roche Holding AG, Fujifilm Holdings Corporation, GE Healthcare, Grail, LLC, Henry Ford Health, Hitachi, Ltd., Hologic, Inc., Illumina, Inc., Invitae Corporation, Koninklijke Philips N.V., Laboratory Corporation of America Holdings, NantOmics, NeoGenomics Laboratories, Inc., Novocure GmbH, Oncologica Limited, Quibim, S.L., Siemens Healthineers AG, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Brain Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Test Type, market is studied across Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, PET Scan, and Spinal Tap.
  • Based on Brain Cancer Type, market is studied across Acoustic Neuroma, Astrocytomas, Chordomas, and Ependymomas.
  • Based on End-User, market is studied across Diagnostic Centers and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidence of brain cancer
      • 5.1.1.2. Growth in the number of private diagnostic centers and rising public-private partnerships
    • 5.1.2. Restraints
      • 5.1.2.1. Heavy costs associated with diagnosis and low awareness about the diagnosis
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancement in diagnostics devices
      • 5.1.3.2. Development of diagnostic approaches for various cancer mutations
    • 5.1.4. Challenges
      • 5.1.4.1. Rising risk of high radiation exposure and stringent regulatory guidelines
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Brain Cancer Diagnostics Market, by Test Type

  • 6.1. Introduction
  • 6.2. Magnetic Resonance Imaging
  • 6.3. Magnetic Resonance Spectroscopy
  • 6.4. PET Scan
  • 6.5. Spinal Tap

7. Brain Cancer Diagnostics Market, by Brain Cancer Type

  • 7.1. Introduction
  • 7.2. Acoustic Neuroma
  • 7.3. Astrocytomas
  • 7.4. Chordomas
  • 7.5. Ependymomas

8. Brain Cancer Diagnostics Market, by End-User

  • 8.1. Introduction
  • 8.2. Diagnostic Centers
  • 8.3. Hospitals & Clinics

9. Americas Brain Cancer Diagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Brain Cancer Diagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Brain Cancer Diagnostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Associated Regional and University Pathologists, Inc.
  • 3. Becton, Dickinson and Company
  • 4. Bristol Myers Squibb Co.
  • 5. F. Hoffmann-La Roche AG by Roche Holding AG
  • 6. Fujifilm Holdings Corporation
  • 7. GE Healthcare
  • 8. Grail, LLC
  • 9. Henry Ford Health
  • 10. Hitachi, Ltd.
  • 11. Hologic, Inc.
  • 12. Illumina, Inc.
  • 13. Invitae Corporation
  • 14. Koninklijke Philips N.V.
  • 15. Laboratory Corporation of America Holdings
  • 16. NantOmics
  • 17. NeoGenomics Laboratories, Inc.
  • 18. Novocure GmbH
  • 19. Oncologica Limited
  • 20. Quibim, S.L.
  • 21. Siemens Healthineers AG
  • 22. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. BRAIN CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. BRAIN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. BRAIN CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BRAIN CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BRAIN CANCER DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE SPECTROSCOPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PET SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SPINAL TAP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ACOUSTIC NEUROMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ASTROCYTOMAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CHORDOMAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EPENDYMOMAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BRAIN CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. BRAIN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. BRAIN CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023